LON:ROQ Roquefort Therapeutics (ROQ) Share Forecast, Price & News GBX 7.62 +0.12 (+1.60%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range 7.25▼ 7.7050-Day Range 6▼ 952-Week Range 5.75▼ 9.40Volume319,082 shsAverage Volume256,879 shsMarket Capitalization£9.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Roquefort Therapeutics (LON:ROQ) StockRoquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.Read More ROQ Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROQ Stock News HeadlinesSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as eyes commercial dealsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as it eyes commercial dealsSeptember 28, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! September 21, 2023 | americanbankingnews.comRoquefort Therapeutics (LON:ROQ) Stock Price Up 9.8%August 17, 2023 | finance.yahoo.comRoquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patentsAugust 9, 2023 | finance.yahoo.comRoquefort Therapeutics making headway with siRNAJune 29, 2023 | proactiveinvestors.comRoquefort Therapeutics highlights significant progress at AGMJune 22, 2023 | proactiveinvestors.comRoquefort Therapeutics hails significant pre-clinical resultsSeptember 28, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! June 22, 2023 | marketwatch.comRoquefort Therapeutics Makes Progress on Cancer TreatmentJune 16, 2023 | finance.yahoo.comRoquefort Therapeutics returns to the market with new study dataJune 13, 2023 | marketwatch.comRoquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive ResultsJune 7, 2023 | marketwatch.comRoquefort Therapeutics Resumes Trading After Publishing 2022 ResultsJune 5, 2023 | proactiveinvestors.comRoquefort Therapeutics eyes second half progressMarch 13, 2023 | proactiveinvestors.comRoquefort Therapeutics has no exposure to SVBMarch 8, 2023 | proactiveinvestors.comRoquefort Therapeutics says new mRNA platform "fits very well"March 8, 2023 | proactiveinvestors.comRoquefort develops a fifth programme using a technology pioneered by Moderna and BioNTechMarch 6, 2023 | proactiveinvestors.comRoquefort Therapeutics establishes scientific advisory boardFebruary 22, 2023 | lse.co.ukRoquefort Thera Regulatory NewsFebruary 21, 2023 | barrons.comRoquefort Therapeutics PLCFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks Randox diagnostic dealFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks first strategic licensing deal with diagnostics firm RandoxJanuary 26, 2023 | finance.yahoo.comRoquefort Therapeutics demonstrates initial safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics demonstrates safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics cancer drugs enjoy pre-clinical successJanuary 9, 2023 | proactiveinvestors.comRoquefort Therapeutics CEO lays out strategy for 2023January 9, 2023 | proactiveinvestors.comRoquefort Therapeutics in out-licensing discussions with 'multiple' large bio-pharma companiesSee More Headlines Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ROQ CUSIPN/A CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.62% Return on Assets-16.57% Debt Debt-to-Equity RatioN/A Current Ratio8.67 Quick Ratio3.07 Sales & Book Value Annual Sales£637.00 Price / Sales15,459.48 Cash FlowGBX 5.10 per share Price / Cash Flow1.49 Book ValueGBX 6 per share Price / Book1.27Miscellaneous Outstanding Shares129,150,000Free FloatN/AMarket Cap£9.85 million OptionableNot Optionable Beta-0.13 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Stephen Paul West B.Com (Age 50)CA, Exec. Chairman Comp: $118.31kMr. Trevor Ajanthan Reginald (Age 51)CEO & Exec. Director Comp: $284.1kProf. Martin J. Evans FRSGroup Chief Scientific Officer & Exec. DirectorDr. Emma MorrisHead of Pre-Clinical ResearchKey CompetitorsCizzle BiotechnologyLON:CIZOxford Cannabinoid TechnologiesLON:OCTPIXICOLON:IXIImmuPharmaLON:IMMBSF EnterpriseLON:BSFAView All CompetitorsInsidersDr Darrin DisleyBought 269,935 shares on 8/1/2023Total: £1.89 M ($7.00/share)Stephen Paul WestBought 15,730 shares on 7/12/2023Total: £94,380.00 ($6.00/share)Stephen Paul WestBought 144,117 shares on 6/26/2023Total: £1.01 M ($7.00/share)Trevor Ajanthan (Ajan) ReginaldBought 35,265 shares on 6/23/2023Total: £246,855.00 ($7.00/share)View All Insider Transactions ROQ Stock - Frequently Asked Questions How have ROQ shares performed in 2023? Roquefort Therapeutics' stock was trading at GBX 6.75 at the start of the year. Since then, ROQ shares have increased by 13.0% and is now trading at GBX 7.63. View the best growth stocks for 2023 here. What is Roquefort Therapeutics' stock symbol? Roquefort Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ROQ." How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Roquefort Therapeutics' stock price today? One share of ROQ stock can currently be purchased for approximately GBX 7.63. How much money does Roquefort Therapeutics make? Roquefort Therapeutics (LON:ROQ) has a market capitalization of £9.85 million and generates £637.00 in revenue each year. The company earns £-1,620,000.00 in net income (profit) each year or GBX (0.02) on an earnings per share basis. How can I contact Roquefort Therapeutics? Roquefort Therapeutics' mailing address is Eccleston Yards, 25 Eccleston Place, London SW1W 9NF, United Kingdom. The official website for the company is www.roquefortinvest.com. The company can be reached via phone at 44 20 3290 9339. This page (LON:ROQ) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.